undamentalytics Newsletter
Sign in

Septerna, Inc. income statement

In fiscal 2025, Septerna, Inc. reported revenue of $46.0m, up 4174.5% on the year before, operating income of −$68.3m (a -148.6% margin) and net income of −$48.9m, or −$1.10 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue014699
Research and development366598121
General and administrative10172934
Operating income2−81−68−44
Income before tax−49−72−49−23
Income tax1−001
Net income4−72−49−24
Diluted EPS$0.29−$7.26−$1.10−$0.54
Diluted shares (average)2m10m44m45m
EBITDA3−79−67−42

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AGIO vs SEPNKYMR vs SEPNSEPN vs XNCRFDMT vs SEPN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Septerna, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Septerna, Inc.